Cardiovascular risk management among individuals with type 2 diabetes and severe mental illness: a cohort study

Diabetologia. 2024 Jun;67(6):1029-1039. doi: 10.1007/s00125-024-06111-w. Epub 2024 Feb 26.

Abstract

Aims/hypothesis: The aim of this study was to compare cardiovascular risk management among people with type 2 diabetes according to severe mental illness (SMI) status.

Methods: We used linked electronic data to perform a retrospective cohort study of adults diagnosed with type 2 diabetes in Scotland between 2004 and 2020, ascertaining their history of SMI from hospital admission records. We compared total cholesterol, systolic BP and HbA1c target level achievement 1 year after diabetes diagnosis, and receipt of a statin prescription at diagnosis and 1 year thereafter, by SMI status using logistic regression, adjusting for sociodemographic factors and clinical history.

Results: We included 291,644 individuals with type 2 diabetes, of whom 1.0% had schizophrenia, 0.5% had bipolar disorder and 3.3% had major depression. People with SMI were less likely to achieve cholesterol targets, although this difference did not reach statistical significance for all disorders. However, people with SMI were more likely to achieve systolic BP targets compared to those without SMI, with effect estimates being largest for schizophrenia (men: adjusted OR 1.72; 95% CI 1.49, 1.98; women: OR 1.64; 95% CI 1.38, 1.96). HbA1c target achievement differed by SMI disorder and sex. Among people without previous CVD, statin prescribing was similar or better in those with vs those without SMI at diabetes diagnosis and 1 year later. In people with prior CVD, SMI was associated with lower odds of statin prescribing at diabetes diagnosis (schizophrenia: OR 0.54; 95% CI 0.43, 0.68, bipolar disorder: OR 0.75; 95% CI 0.56, 1.01, major depression: OR 0.92; 95% CI 0.83, 1.01), with this difference generally persisting 1 year later.

Conclusions/interpretation: We found disparities in cholesterol target achievement and statin prescribing by SMI status. This reinforces the importance of clinical review of statin prescribing for secondary prevention of CVD, particularly among people with SMI.

Keywords: Bipolar disorder; Cardiovascular risk; Clinical care; Cohort study; Depression; Diabetes management; Health disparities; Mental disorders; Schizophrenia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Bipolar Disorder / complications
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / epidemiology
  • Blood Pressure / physiology
  • Cardiovascular Diseases* / epidemiology
  • Cholesterol / blood
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / epidemiology
  • Female
  • Glycated Hemoglobin / metabolism
  • Heart Disease Risk Factors
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Mental Disorders / epidemiology
  • Middle Aged
  • Retrospective Studies
  • Schizophrenia / drug therapy
  • Schizophrenia / epidemiology
  • Scotland / epidemiology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Glycated Hemoglobin
  • Cholesterol